ASTRO issues updated clinical guideline for whole breast radiation therapy

Accelerated treatment now recommended for most patients, including younger patients, those with more advanced disease and those receiving chemotherapy

ARLINGTON, Va., March 12, 2018 – The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofractionated therapy.

Breast cancer is the most common malignancy treated with radiation therapy in the United States, and whole breast irradiation (WBI) is the most frequently used type of radiation delivered for these tumors. With hypofractionated WBI, patients receive larger doses of radiation across fewer treatment sessions—typically completing treatment in three to four weeks, compared with five to seven weeks for conventional treatment.

Reflecting current evidence from clinical trials and large cohort studies, the new guideline recommends hypofractionated WBI for breast cancer patients regardless of age, tumor stage and whether they have received chemotherapy. It replaces the existing ASTRO WBI guideline published in 2011.

"Previously, accelerated treatment was recommended only for certain patients, including older patients and those with less advanced disease, but recent long-term results from several large trials strongly support the safety and efficacy of accelerated treatment for most breast cancer patients,” said Benjamin Smith, MD, co-chair of the guideline task force and an associate professor of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston. "Conventional therapy does not provide an incremental benefit in either tumor control or side effects compared to hypofractionated WBI."

Despite the data supporting accelerated treatment, large numbers of eligible breast cancer patients are not receiving shorter courses of radiation therapy. A 2013 JAMA study found an adoption rate of approximately 30 percent, and a 2017 analysis for Kaiser Health News indicated that fewer than half of patients over age 50 with early-stage disease receive the accelerated treatment.

“Hypofractionated radiation therapy offers patients a more convenient and lower cost option for their treatment without compromising the likelihood that their cancer will return or increasing their risk of side effects,” said Reshma Jagsi, MD, DPhil, co-chair of the task force and a professor of radiation oncology at the University of Michigan in Ann Arbor. "A shorter course of radiation equates to more time with family, less time away from work and lower treatment costs. We hope that this guideline encourages providers to counsel their patients on options including hypofractionation."

The guideline provides clinical guidance for dosing, planning and delivering WBI with or without an additional "boost" of radiation therapy to the tumor bed. Full recommendations and supporting evidence are provided in the guideline; key recommendations are as follows:

Delivery and Dosing of WBI (without irradiation of regional nodes)

Treatment decisions, including decisions between hypofractionated and conventional approaches, should be individualized to each patient and shared between the patient and their physician(s).

For women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated WBI to a dose of 4000 Centigray (cGy) in 15 fractions or 4250 cGy in 16 fractions.

The decision to offer hypofractionated therapy should be independent of the following factors: tumor grade; whether the tumor is in the left or right breast; prior chemotherapy; prior or concurrent trastuzumab or endocrine therapy; and breast size, provided that homogenous dosing can be achieved. It may be independent of the following factors: hormone receptor status; HER2 receptor status; margin status following surgical resection; and age.

For patients with DCIS, hypofractionated WBI may be used as an alternative to conventional fractionation.

Radiation Boost

All decisions related to use and dosing of the boost should be discussed between the patient and provider(s) and consider individual patient, tumor, and treatment factors. These decisions also should be independent of whether the patient received conventional or hypofractionated WBI.

For invasive cancer cases, a tumor bed boost is recommended for patients with a positive margin following surgical resection, patients age 50 and younger, and patients age 51 to 70 if they have a high-grade tumor. Omitting a tumor bed boost is suggested for patients with invasive cancer who are older than 70 and have low-to-intermediate-grade, hormone-positive tumors resected with widely negative margins.

For DCIS, a boost is recommended for patients age 50 and younger, patients with high-grade tumors and/or those with positive or close margins following resection. A boost may be omitted for patients with DCIS who are older than 50; have been screen detected; have smaller, low-to-intermediate grade tumors; and have widely negative margins following surgery.

Recommendations for boost dosing, sequencing and radiation delivery techniques are outlined in the guideline.

Preferred Techniques for Treatment Planning

Treatment plans should be individualized after consideration of many factors, including tumor characteristics, patient anatomy and comorbidities.

Three-dimensional conformal (3-D CRT) treatment planning with a forward planned, field-in-field technique is recommended to achieve homogenous radiation dosing and full coverage of the tumor bed.

Approaches that incorporate deep inspiration breath hold, target and organ-at-risk contouring and optimal patient positioning are recommended to minimize the radiation dose affecting nearby organs and normal tissue, including the heart, lungs and opposite breast.

The guideline was based on a systematic literature review of studies published from January 2009 through January 2016. A total of 528 abstracts were retrieved from PubMed, and the 100 articles that met inclusion criteria were evaluated by a 15-member task force of radiation oncologists who specialize in breast cancer, a medical physicist and a patient representative. The guideline was approved by ASTRO’s Board of Directors following a period of public comment. The guideline has been endorsed by the Royal Australian and New Zealand College of Radiologists (RANZCR) and the Society of Surgical Oncology (SSO).

ASTRO's clinical guidelines are intended as a tool to promote appropriately individualized, shared decision-making between physicians and patients. None should be construed as strict or superseding the appropriately informed and considered judgments of individual physicians and patients.

“Radiation Therapy for the Whole Breast: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline” is available as a free access article in Practical Radiation Oncology, ASTRO’s clinical practice journal. For a copy of the guideline or to interview Dr. Smith, Dr. Jagsi or outside experts in breast cancer, contact ASTRO’s media relations team at press@astro.org or 703-286-1600.

# # #

Multimedia and more on breast cancer and radiation therapy:

ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the world’s largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three peer-reviewed journals, the International Journal of Radiation Oncology • Biology • Physics (redjournal.org), Practical Radiation Oncology (practicalradonc.org) and Advances in Radiation Oncology (advancesradonc.org); developed and maintains an extensive patient website, RT Answers (rtanswers.org); and created the Radiation Oncology Institute (roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org, sign up to receive our news and follow us on our blogFacebook and Twitter.

Rosacea may be a visible warning marker for hidden, potentially serious diseases

 

VANCOUVER, March 13, 2018 /CNW/ - Canadians who have rosacea should be aware of associations between the disease and increased risk for a variety of disorders - many with potentially serious consequences – in order to detect these diseases at the earliest stage, according to Dr. Jason Rivers, a Vancouver dermatologist and president of the not for profit Acne and Rosacea Society of Canada.

An analysis(1) published early this year showed the highest associations with rosacea were diseases in 4 categories: cardiovascular, gastrointestinal, neurological and autoimmune. Recent studies have shown those with rosacea have higher risks for:

  • Cardiovascular disease – 4 times higher
  • Gastroesophageal reflux disease (GERD) - 4 times
  • Crohn's disease - almost 3 times
  • Inflammatory bowel disease (IBD) - 2 times
  • Celiac disease - 2 times
  • Type 2 diabetes - 2.5 times

People with rosacea also have a 10 times higher risk of food allergies, 7.5 times greater risk of urogenital diseases (affecting the urinary tract or reproductive organs) and 4 times elevated risk for respiratory diseases.

"These studies show association but do not demonstrate cause," says Dr. Rivers. "For example, rosacea is not caused by these conditions nor do these conditions cause rosacea. These studies show that these disorders tend to co-exist together where if you have one, you have a higher chance of having the other."

The role of inflammation – the immune system's response to potential threat or harm - appears to be a common thread. Rosacea, affecting 3 million Canadians, is an inflammatory skin condition characterized by facial redness, pimples and sometimes irritated eyes. Inflammation is thought to play a role in these cardiovascular, gastrointestinal, neurological and autoimmune diseases.

"Inflammation present in these other conditions is hidden within the body," Dr. Rivers added. "However, rosacea appears on the skin making it a visible marker of inflammation that may be helpful as a warning sentinel for these other conditions."

An important consideration for those with rosacea is that being at risk for these conditions does not mean he or she will go on to develop any of these disorders. "Disease development is different for everyone. Family history, personal history, age, gender, environment, lifestyle and other factors all play a role in disease development," he adds.

"However, simply being aware of the associations of rosacea and elevated risk for these potentially serious conditions can help with early detection, diagnosis and treatment," said Dr. Rivers.

Reference:

  1. Rosacea comorbidities and future research: The 2017 update by the National Rosacea Society Expert Committee. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D.J Am Acad Dermatol. 2018 Jan;78(1):167-170. doi: 10.1016/j.jaad.2017.06.150

About the Acne and Rosacea Society of Canada:

The society, a national, not for profit organization, offers hope and help to sufferers by providing independent, reputable and current information on rosacea and raising awareness. For more, visit www.RosaceaHelp.ca

About Rosacea Awareness Month

Rosacea Awareness Month, April 2018, was designated by the Acne and Rosacea Society of Canada (www.RosaceaHelp.ca) to raise awareness about rosacea, a common skin condition affecting more than 3 million Canadians that can cause significant physical and emotional effects.

Media resources:

  • Dermatologists with the society are available for media interviews
  • 2018 Rosacea Facts and Stats Sheet
  • Images of rosacea

During April, the society will be posting news to our bilingual website, www.RosaceaHelp.ca, and Facebook Page, Rosacea Help, and @RosaceaHelp on Twitter.

For more information or to organize an interview with spokespeople for Acne and Rosacea Society of Canada:

Dr. Jason Rivers, Vancouver; Dr. Benjamin Barankin, Toronto; Dr. Jerry Tan, Windsor; Dr. Ari Demirjian and Dr. Jean-Francois Tremblay, Montreal; Dr. Marni Wiseman, Winnipeg; Dr. Catherine Zip, Calgary, Dr. Shannon Humphrey and Dr. Marcie Ulmer, Vancouver

SOURCE Acne and Rosacea Society of Canada

Meet the ISSA 2, FOREO’s New Generation of Revolutionary Toothbrushes
Merging Exceptional Dental Hygiene with Impeccable Style
STOCKHOLM, SWEDEN, 12 March 2018; The world’s biggest beauty tech brand, FOREO, has just launched the toothbrush of the future -  the ISSA 2, a sonic electric toothbrush that combines state-of-the-art technology with unparalleled durability: a one-hour charge lasts up to an incredible 365 uses. Setting a new global standard for advanced oral care, the revolutionary, new generation toothbrush has become a firm favorite of the who’s who of lifestyle bloggers and it doesn’t stop there -  the award-winning ISSA’s influence even extends to outer space, and in 2017 it made a cameo appearance in Episode 5 of Star Trek: Discovery.
An ultra-hygienic alternative to both manual brushing and conventional nylon-bristled electric toothbrushes, ISSA 2 differs from traditional models by way of its material; medical-grade silicone. In addition to the standard version with the hybrid brush head made of nylon and silicone combination , ISSA 2 is also available in an exclusive “Sensitive” Set which includes one hybrid brush head and one brush head made completely out of silicone for those with specially sensitive gums.
Providing a comfortable and secure grip on the brush’s ergonomic handle, the material presents several key advantages:
  • Soft, flexible brush head reaches all corners of the mouth
  • Quick-drying, non-porous and 100% waterproof
  • Resists the buildup of bacteria for up to 10,000x less bacteria than nylon-bristled toothbrushes
  • Soft silicone bristles are gentle on gums and won’t scratch tooth enamel
Designed to be used like a manual toothbrush, the ISSA 2 does not oscillate like conventional electric models. Instead it incorporates T-Sonic technology to pulsate at a frequency of 11,000 pulsations per minute for micro-sweeps that effectively, yet gently, clean teeth and massage gums. A superior brushing experience for a whiter, brighter smile, ISSA 2 removes plaque for total oral care and is particularly suited to those with sensitive gums, or for whom erosion of tooth enamel is a concern.
Like all FOREO devices, ISSA 2 comes with integrated and smart Swedish design. Its features include:
  • 16 variable speeds, as well as a built-in timer to prevent over-brushing.
  • Rechargeable via USB, lasts up to 365 uses.
  • Ideal for traveling: travel lock feature and no bulky charging dock to transport.
  • Savvy oral health investment: ISSA 2’s hybrid brush head lasts for 6 months before needing to be replaced, while the sensitive 100% silicone one lasts for the whole year
  • Two-year limited warranty and a 10-year quality guarantee.
Stylish and chic, ISSA 2 by FOREO also looks the part, and is available in four striking colors to brighten up any bathroom surface, with the Sensitive set coming in two vibrant colors.
FOREO CEO Paul Peros said; “With the ISSA 2, we sought to offer a brand new way of cleaning teeth that feels completely unique compared to anything else out there. From its state-of-the-art material to its revolutionary design, ISSA 2 remains a truly watershed product in a market that had seen little in the way of innovation for far too long. Star Trek got it right - the ISSA 2 is very much the toothbrush of the future.”
ISSA 2 is just one of FOREO’s expanding and innovative range of skincare and dental devices. Established in 2013, the Swedish brand enjoys global success and has won more than 85 design and beauty awards internationally. The ISSA 2 and the ISSA 2 Sensitive Set is available now at www.foreo.com for $169-$189.

When it comes to the great ideas – many were devised while the innovator was sleeping – or in a dream.

In fact, Einstein’s theory of relativity has been voted the greatest idea ever inspired during sleep.

That's according to a new international poll researched by Calm, the popular meditation and sleep app.

www.calm.com

The full list and additional info and explanations are below – including tips/hacks on how people can learn to “sleep-storm” or brainstorm while sleeping to be more creative.

-------

Q. The following ideas were all conceived during sleep and/or inspired by dreams.

Which ONE of these ideas would you consider the best or “greatest” idea?

Rank    Idea    % of respondents

1 - The theory of relativity, by Einstein - 23%

2 - The periodic table of chemical elements - 13%

3 - The invention of the sewing machine - 10%

4 - The model of the atom, conceived by physicist Neils Bohr - 7%

5 - “Yesterday”, the Beatles song by Paul McCartney - 5%

6 - “Terminator”, the movie(s) and movie character - 3%

6 - The principles of analytical geometry, devised by René Descartes - 3%

8 - “Frankenstein”, the novel by Mary Shelley - 2%

8 - “I Can’t Get No Satisfaction”, the Rolling Stones song by Keith Richards - 2%

10 - “The Strange Case of Dr. Jekyll and Mr. Hyde”, the novella by Robert Louis Stevenson - 1%

10 - “Kubla Kahn”, the poem by Samuel Taylor Coleridge - 1%

10 - The discovery of the structure of the benzene molecule - 1%

None of these - 15%

Don’t know - 16%

-----

The poll was commissioned by the app Calm, recently named Apple’s App of the Year.

Calm helps users relax and sleep with a growing library of sleep music and 80+ bedtime stories for grown-ups known as Sleep Stories.

“It’s a stunning list,” says Alex Tew, co-founder of Calm.

“Sleep is not just vital to health but perhaps the greatest single source of creativity.”

Some items to note:

Einstein’s famous theory comfortably topped the poll with 23% of the vote ahead of the periodic table on 13% and the sewing machine on 10%.

No other idea, including “Yesterday” (5%), polled more than single figures.

Einstein’s journey to the theory of relativity reportedly began with a dream about a field of cows surrounded by an electric fence. But when he told the farmer who he met in the dream what he’d seen and the farmer’s account differed, it gave Einstein the key insight that the same event could look different from different perspectives.

The periodic table of chemical elements seems to have appeared fully formed to the Russian chemist Dmitri Mendeleev in his sleep on the night of February 17, 1869. “I saw in a dream a table where all the elements fell into place as required,” he wrote. “Awakening, I immediately wrote it down on a piece of paper. Only in one place did a correction later seem necessary.”

“Yesterday”, The Beatles song whose tune came to Paul McCartney in his sleep one night in 1964, polled highest of any idea from the arts rather than sciences, ranking fifth overall – one behind the model of atom, devised by the Danish physicist Neils Bohr.

Sixth place in Calm’s poll went jointly to Terminator, the movie character which first appeared to director James Cameron in a dream, and the principles of analytic geometry devised by René Descartes, the 17th century French philosopher and mathematician who reputedly slept up to 12 hours a day.

Keith Richards of The Rolling Stones did not even have to write down the opening verse of the great Stones’ song, “I Can’t Get No Satisfaction”. When he woke in the morning of May 7, 1965, he found that he had unwittingly committed it to a tape recorder during the night.

-----

Life-Hacks: Four Ways To Come Up With Ideas In Your Sleep

Is “Sleep-storming” the new brainstorming?

Not only is it possible to boost your odds of generating ideas while you sleep but there’s even a scientific name for it:

“Structured unconscious generative ideation”.

A non-scientific name for it might be “sleep-storming” – as in brainstorming, done solo while you’re asleep.

But can you really train your brain to harvest your sleep for ideas? And is sleep-storming the new brainstorming?

Here are four simple ways suggested by Calm to increase your chances of coming up with ideas while you sleep – and/or capturing the ones that you do.

1 - Keep a Notebook Handy + Write Down Your Dreams

It can be hard to remember your dreams and/or any ideas they inspire. So, always keep a notebook by your bed. Get into the habit of writing down your dreams – and any ideas they might trigger – immediately on waking and almost before you are fully awake. Write down every dream you can recall rather than being selective. The act of writing them down helps you build a relationship with your subconscious, which should in turn help improve your dream recall.

“I always keep a notebook by my bed,” says Michael Acton-Smith, co-founder of Calm. “I often wake up in the night to jot down ideas – and then do so again first thing in the morning.”

2 - Ask Your Subconscious The Question You’re Trying to Answer

“Never go to sleep without a request to your subconscious”, advised Thomas Edison, the great inventor. So, instead of just falling asleep, brief or prime your subconscious to generate new ideas. Before falling asleep, ask yourself the question that you’re trying to answer; then, finally, focus on something else, such as reading or relaxation techniques.

3 - Wake Yourself Mid-Sleep

Waking yourself while dreaming or starting to fall asleep was a technique used by both the artist Salvador Dalí and the inventor Thomas Edison. Dali would put a tin plate on the floor and then sit on a chair beside it, holding a spoon over the plate. He’d then try to doze off so that the spoon would fall and wake him. Edison did similar but with ball bearings and a saucepan. The aim for both was to jolt themselves awake in order to capture ideas from their dreams.

4 - Learn to Have “Lucid Dreams”

Lucid dreaming is the sense of being consciously aware that you are dreaming. This state can help you to explore ideas, control elements of your dream and have better than normal dream recall than. Learning to dream lucidly takes time and practice. You need to try repeating a mantra telling yourself that you want to dream or know that you are dreaming and, for example, want to be aware that you are dreaming and to remember the dream.

 
Mindfulness Meditation Reduces Incidence of Major Depression

Among primary care patients with subthreshold depression, mindfulness meditation training reduces the incidence of major depression and improves depression symptoms.  A randomized controlled trial of adults with subthreshold depression compared a usual care group in which there was no psychological intervention (n=116) with a behavioral activation group focused on mindfulness training (n=115). Intervention participants were invited to attend weekly two-hour mindfulness training sessions for eight consecutive weeks. At 12 months, there was a statistically significant difference in the incidence of major depressive disorder between groups (11 percent in the mindfulness group compared to 27 percent in usual care).  Mindfulness training also had a small effect in reducing depression symptoms (between-group mean difference = 3.85). Other secondary outcomes demonstrated no significant change. The authors suggest that, for patients with subthreshold depression who have not had a major depressive episode in the past six months, mindfulness training is a feasible method of preventing major depression. The authors plan future research into the cost-effectiveness, health service use implications, and acceptability of mindfulness training.

Treating Subthreshold Depression in Primary Care: A Randomized Controlled Trial of Behavioural Activation With Mindfulness

Samuel Y.S. Wong, MD, et al

The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong

Kong, New Territories, Hong Kong

 

Asthma Management Tools Improve Asthma Control and Reduce Hospital Visits

A set of comprehensive asthma management tools helps decrease asthma-related visits to the emergency department, urgent care or hospital and improves patients’ asthma control. The Asthma APGAR tools, including an asthma control assessment completed by patients and linked to an asthma management algorithm, were tested in a randomized controlled study of 18 family medicine and pediatric practices across the United States. The study compared outcomes in more than 1,000 patients with persistent asthma aged five to 45 years using Asthma APGAR tools versus usual care. The proportion of patients reporting an asthma-related emergency department, urgent care or hospital visit in the final six months of the study differed significantly between groups: 11 percent for intervention groups and 21 percent for usual care groups.  Between baseline and one year, the percentage of patients whose asthma was in control increased significantly in the intervention group (14 percent) compared to the usual care group (3 percent), with a trend toward better control scores and asthma-related quality of life in the intervention group at 12 months. Intervention practices also significantly increased their adherence to three or more elements of the National Asthma Education and Prevention Program guidelines compared to usual care practices. Participating practices reported that changing practice to incorporate the Asthma APGAR tools was challenging, but the tools themselves were perceived as useful and efficient. The authors suggest that the Asthma APGAR tools are effective for asthma management in the primary care practice setting.

Use of Asthma APGAR Tools in Primary Care Practices: A Cluster-Randomized, Controlled Trial

Barbara P. Yawn, MD MSc FAAFP, et al
Olmsted Medical Center, Rochester, Minnesota

 

New Analysis Recommends Against Using Digital Rectal Exam in Primary Care

Although the digital rectal exam is widely used in primary care to screen for prostate cancer, a new study finds limited data to support its effectiveness. The study, a meta-analysis of previous research, found that the quality of available evidence was very low and that existing studies were at risk of bias. In the analysis, pooled sensitivity of the digital rectal exam among primary care physicians was 0.51 and pooled specificity was 0.59. Given the considerable lack of evidence supporting its efficacy, the authors recommend against routinely performing digital rectal exams to screen for prostate cancer in the primary care setting.

Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis
Jason Profetto, MD, CCFP, et al

McMaster University, Hamilton, Ontario, Canada

 

Patients with Multiple Conditions Receive Higher Level of Care in Affluent Areas

Patients with multimorbidity—two or more long-term medical conditions—have complex health care needs, often requiring higher levels of care than other patients. According to a new study, however, patients with multimorbidity in affluent areas receive longer doctor visits, greater perceived empathy, and more patient-centered care than comparable patients in socioeconomically deprived areas. Researchers in Scotland analyzed 659 routine visits to general practitioners in deprived and affluent areas, as well as patient ratings of general practitioner empathy. In affluent areas, multimorbid patients received longer consultations than other patients (13 minutes versus 9 minutes) while in deprived areas, consultation length was about the same for both groups (10 minutes). Similarly, patients with multimorbidity in affluent areas found GPs to be more empathetic and, according to video analysis, more attentive to their disease and illness experience. There were no such differences between similar groups in deprived areas. If primary care is to succeed in narrowing health inequalities, the authors state, action is needed to ensure that patients with multimorbidity in lower socioeconomic areas receive the same level of care and attention as patients in affluent areas.

Multimorbidity and Socioeconomic Deprivation in Primary Care Consultations

Stewart W Mercer, MBchB, PhD, et al

University of Glasgow, Glasgow, Scotland

 

Oseltamivir Does Not Increase Risk of Suicide in Children

A new study finds that use of oseltamivir, an antiviral drug used to treat influenza A and B, does not increase risk of suicide in children. Researchers identified 21,047 children between one and 18 years of age who attempted suicide during the 2009-2013 influenza seasons. Of those, 251 had been exposed to oseltamivir. Mean age was approximately 15 years, and underlying mental health diagnoses were common (65 percent). Because the observed association between oseltamivir and suicide could potentially be confounded by underlying influenza infection, the analysis was repeated with influenza diagnosis alone (without oseltamivir use) as the exposure. Using this novel study design, which reduced statistical concerns found in previous studies, researchers did not find an association between oseltamivir or influenza diagnosis (only) and suicide.

The Relationship Between Oseltamivir and Suicide in Pediatric Patients

James W. Antoon, MD, et al

Children’s Hospital University of Illinois, Chicago, Illinois

 

No Increase in Shared Decision-Making for PSA Testing but Discussions Have Broadened

Although health care organizations differ in their recommendations for use of prostate-specific antigen testing for prostate cancer screening, they agree that the decision to undergo PSA testing should be shared by patients and clinicians. A new study finds that although there has been no increase in shared decision-making for PSA testing, the content of discussions has become more comprehensive. The study compared responses to the National Health Interview Survey in 2010 and 2015 among men age 50 and older (n=9598). In this nationally representative sample, a similar proportion (approximately 60 percent) of men with recent PSA testing reported one or more elements of shared decision-making in both 2010 and 2015. They also reported a modest shift away from discussions limited to the advantages of PSA testing toward full shared decision-making in which advantages, disadvantages, and uncertainties were discussed (12 percent of recently-tested men in 2010 compared to 17 percent in 2015). One in 10 men who did not receive PSA testing reported receiving one or more elements of shared decision-making, a number which did not change during the study period. The results suggest that, contrary to guideline recommendations, many men receiving PSA testing still do not receive shared decision-making and a limited number of men without PSA testing receive one or more shared decision-making elements. The authors call for new and innovative strategies to achieve more widespread application of shared decision-making for men considering PSA testing.

Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United

States

Stacey A Fedewa, PhD, MPH, et al
American Cancer Society, Atlanta, Georgia

 

Electronic Consultation System Improves Access to Specialty Care

An electronic consultation system designed to reduce excessive wait times for appointments with specialists experienced exponential growth during a recent five-year period. The Champlain BASE eConsult service was created to provide primary care clinicians in Ontario, Canada with a range of high quality and timely (up to one week) specialty input. Unlike electronic consultation systems that provide direct links between clinicians, this service enables primary care clinicians to search a directory, select a specialist, and contact her/him through a secure channel. The system, created in 2010, had four completed eConsult cases in April, 2011 compared to 769 cases in April, 2016, with primary care clinicians submitting 14,105 cases to 56 specialties during the 5-year period. Specialties receiving the highest number of eConsults were dermatology (17 percent); endocrinology, obstetrics/gynecology, and hematology (7 percent each); cardiology (6 percent); and neurology (6 percent). Specialists responded in a median of 21 hours; in 75 percent of cases they responded within three days. Self-reported billing time for specialists ranged from less than 10 minutes (in 48 percent of cases) to more than 20 minutes (4 percent of cases). By the end of the study period, approximately 80 percent of primary care clinicians in the region had adopted the eConsult service, which is poised for expansion across Canada. The study demonstrates that, once integrated into a practice’s specialty referral workflow, the eConsult service has the potential to reduce wait times for specialty care.

Sustainability of a Primary Care-Driven eConsult Service

Clare Liddy, MD, MSc, CCFP, et al

C.T. Lamont Primary Health Care Research Centre, Ottawa, Ontario, Canada

 

Health Care Reform and EHR Design Should Be Built Around Patients’ Goals

Meaningful reform of primary care should not only address the provision, documentation and payment of care; it should be based on patients’ goals for their lives and health, with corresponding redesign of electronic health records. A report from an international team of primary care researchers recommends that the current problem-oriented fee-for-documentation structure of EHRs be replaced by a framework built around life and health goals. This focus would not only better serve patients; it would also help refocus medical professionals on the full scope of human health. To begin the process of creating goal-directed electronic health records, the authors suggest incorporating core patient profile and health planner functions into existing EHRs and creating linkages between patient characteristics and other parts of the EHR. If patient attributes captured by EHRs are expanded to include actionable sociocultural and socioeconomic information, life and health goals, care preferences, and personal risk factors, they can be leveraged by other EHR components so that patients and clinicians can work together to develop personalized care. The authors point out that, although numerous systemic and administrative health care innovations have been tried, the problem-oriented approach to care and its conceptual image coded into the medical record remain the same across innovations. If patient life and health goals are to drive health care and medical record design, shifts will also need to occur in health care delivery, measurement, and payment. The authors call for research into how patients and health care teams can partner effectively using goal-directed health records.

Moving From Problem-Oriented to Goal-Directed Health Records

Zsolt J. Nagykaldi, PhD, et al

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

 

Physicians’ Work Should Focus on Personalized Care, Not Transactional Tasks

Shifting physicians’ roles from transactional tasks to personalized care would best serve patients, physicians and society. According to a newly-articulated vision of shared care, physicians should reduce their roles in transactional aspects of care, such as gathering and entering data, providing disease-specific patient education, and providing most preventive care. Instead, such duties should be filled by other members of the health care team with complementary skills, leaving physicians to diagnose and help patients meet personal goals and objectives. Physicians’ would provide personalized care by synthesizing data from diverse, often discordant sources; adjudicating the competing needs of multiple conditions; adjusting patients’ treatment plans to align with their goals and preferences; and advocating for patients in a complicated, fragmented health care environment. To make this approach a reality, changes would need to occur on multiple levels including health care organization and delivery, technology, reimbursement, medical education, and practice and physician “buy-in.” The authors state that their vision would meet the needs of patients and society while closing the gap between physicians’ intended patient care mission and their current transactional roles. In the process, they explain, physicians could discover joy, purpose, and meaning in their work.

From Transactional Tasks to Personalized Care: A New Vision of Physicians' Roles

David B. Reuben, MD, et al

David Geffen School of Medicine at UCLA, Los Angeles, California

 

Clinicians’ Skills in Narrative Can Help Chronically Ill Patients Heal

“What patients bring to their clinicians is their stories,” writes behavioral scientist Thomas Egnew. It is through these stories that clinicians try to understand and treat patients’ health. When patients experience chronic or life-threatening illness and their suffering increases, clinicians can take on the role of holistic healer by addressing the inevitable existential conflicts in patients’ narratives and helping them edit their stories to promote acceptance and meaning. In this guiding role, Egnew explains, clinicians can help patients transcend suffering, “assume the mantle of their heritage as healers,” and find meaning in their work.
A Narrative Approach to Healing Chronic Illness
Thomas R. Egnew, EdD, LICSW

University of Washington School of Medicine, Seattle, Washington

 

A Patient Embraces the “Pathless Trek” into Chronic Illness

For a young woman with ulcerative colitis, a total colectomy (removal of the colon) marks the end of an illness and the beginning of a journey of personal discovery. Adi Finkelstein, PhD, describes her physical illness and the decision to undergo a colectomy after which, her surgeon promised her, she would have a new life. Over time, she did indeed build a new life, although perhaps not the one her surgeon envisioned. Her journey included letting go of her desire to be an exemplary patient and embracing the liberation that came with accepting her disability, as well as a career researching and teaching medical and nursing students about chronic illness. Living with her own disability while helping others better understand chronic illness is, she writes, “[a] paradox that sustains me.”
You Will Have a New Life

Adi Finkelstein, PhD

Jerusalem College of Technology, Jerusalem, Israel

A Family Physician Reflects on Community, Retirement, and Our Sagging Bodies

As a family physician approaches retirement, he reflects on the next chapter of his life with feelings of freedom and fear. “To live without the vestments of a career,” he realizes, “is a test of faith.” He finds comfort in knowing that his community will be well cared for by a new generation of physicians. On a more personal level, he is both surprised and freed by his aging body, encouraging us to “relax our grip on life, just as our skin has relaxed its grip on us.” Ultimately, he puts his faith in the knowledge that, more than three decades ago, he was called to a career in medicine. “Therein lies the hope that I will be called again.”

When It’s Time to Retire: Notes From the Afterlife

David Loxterkamp, MD
Seaport Community Health Center, Belfast, Maine

 

Core Outcomes Established for Multimorbidity Research

According to a panel of international experts, clinical trials of multimorbidity should measure and report, at minimum, quality of life, mortality, and mental health outcomes. Twenty-six multimorbidity researchers, clinicians, and patients from 13 countries participated in a Delphi Panel and reached consensus on 17 core outcomes for multimorbidity research. The highest ranked outcomes were health related quality of life, mental health outcomes and mortality. Other outcomes were grouped into overarching themes of patient-reported impacts and behaviors (treatment burden, self-rated health, self-management behavior, self-efficacy, adherence); physical activity and function (activities of daily living, physical function, physical activity); outcomes related to the medical visit (communication, shared decision making, prioritization); and health systems outcomes (healthcare utilization, costs, quality of healthcare). The authors suggest that, when designing studies to capture important domains in multimorbidity, researchers consider the full range of outcomes based on study aims and interventions.

A Core Outcome Set for Multimorbidity Research (COSmm)

Susan Smith, MD, MSc, et al
HRB Centre for Primary Care Research, Royal College of Surgeons, Dublin, Ireland

 

Innovations in Primary Care: Citizen Engagement and Team-Based Ordering of Labs

Innovations in Primary Care are brief one-page articles that describe novel innovations from health care’s front lines. In this issue:

  • Citizen Engagement in Primary Care – A primary care organization uses methods of citizen engagement to gather recommendations from a representative group of patient advisors to prioritize areas for practice improvement.
  • Ordering Labs as a Team – A primary care practice shifted its lab ordering procedure from a clinician activity to a team-based process.
###
Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines. Launched in May 2003, Annals is sponsored by seven family medical organizations, including the American Academy of Family Physicians, the American Board of Family Medicine, the Society of Teachers of Family Medicine, the Association of Departments of Family Medicine, the Association of Family Medicine Residency Directors, the North American Primary Care Research Group, and the College of Family Physicians of Canada. Annals is published six times each year and contains original research from the clinical, biomedical, social and health services areas, as well as contributions on methodology and theory, selected reviews, essays and editorials. Complete editorial content and interactive discussion groups for each published article can be accessed free of charge on the journal’s website, www.annfammed.org.

Government of Canada supporting innovative health research at the University of Regina

 

Researchers receive funding for cutting-edge research projects to study addiction and the health of personal support workers

REGINA, March 12, 2018 /CNW/ - Scientific discovery holds the key to finding solutions to many of the economic, social, and health challenges we face as a nation and around the world. That is why the Government of Canada proudly supports science in a number of key areas, which is ensuring Canadians thrive in the years to come.

Today, while visiting the University of Regina, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, highlighted a recent federal investment of $937,000 for health research at the University of Regina. This support, through the Canadian Institutes of Health Research (CIHR), is part of a larger investment of $372M to enable researchers to study a full spectrum of health issues affecting the lives of Canadians.

While visiting the university, Minister Goodale met with Dr. Randy Johner, who received $451,000 to explore the use of smartphones and tablets to deliver culturally adapted substance addiction treatment support for people in remote and rural areas. Research has shown that the use of technology devices for delivering substance addiction treatment is not only cost-efficient when compared to treatment delivered by a counselor, but that it is also effective at engaging and treating patients with substance addiction issues.

The Minister also took a moment to recognize the work of the University of Regina's Dr. Shanthi Johnson. Dr. Johnson's team received a CIHR grant of $485,000 to enroll older adults receiving home care and their personal support workers in a home support exercise program. The goal of Dr. Johnson's project is to improve the physical health and reduce the incidence of falls among older adults while lowering rates of musculoskeletal disorders among personal support workers, whose jobs often result in strains and injuries from repeated lifting and carrying.

Quotes

"Congratulations to the researchers who have received these CIHR grants. Your important work holds the key to saving lives, discovering new treatments, scientific breakthroughs, the creation of the new knowledge that is at the core of advances in health, as well as achieving long-term cost savings in the health care system."
The Honourale Ralph Goodale
Minister Public Safety and Emergency Preparedness  

"This $372 million represents an enormous investment in health research for the science community and benefits all of Canada. Through these grants, CIHR is supporting researchers at all career stages, across the entire country, and in all areas of health research. Our investigators have made Canada a global leader in health research."
Dr. Roderick R. McInnes, CM, O.Ont, MD, PhD, FRSC
Acting President, Canadian Institutes of Health Research

"University of Regina researchers are dedicated to improving the health of Canadians. Whether through developing technology that is able to provide culturally centred substance addiction support or by implementing exercises designed to improve health, reduce falls and lower rates of musculoskeletal disorders in older adults and their continuing care aides, these made-in-Saskatchewan innovations are truly changing lives for the better."
Dr. Vianne Timmons
President and Vice-Chancellor, University of Regina

"I am very excited to receive this CIHR award. For the next three years, our multidisciplinary team of researchers from social work, engineering, sociology, medicine and nursing, will develop and pilot substance use treatment interventions for individuals with diverse learning needs, while using innovative technologies to develop a culturally-informed application (App). This project will build university and community partnerships, with the direct involvement of the Métis Addictions Council of Saskatchewan Inc. and their community members who will assist with creating and testing the App.
Dr. Randy Johner
Associate Professor of Social Work, University of Regina

At the Canadian Institutes of Health Research (CIHR) we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.

 

SOURCE Canadian Institutes of Health Research

Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

 

  • ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
  • For the first time, adding a lipid-lowering therapy to maximally-tolerated statins was associated with reduced death from any cause
  • More pronounced effect observed in patients with baseline LDL-C levels at or above despite maximally-tolerated statins, who are at high risk of suffering a future event; in this group, Praluent reduced risk of major adverse cardiovascular events by 24% and was associated with a 29% lower risk of death overall
  • In this 18,924-patient, long-term trial, the safety profile of Praluent was consistent with previous trials and no new safety issues were observed

LAVAL, QC, March 10, 2018 /CNW Telbec/ - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event such as a heart attack. Results from the trial was presented today during a late-breaker session at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Florida and are available here.

Key findings include:

  • On the primary endpoint, Praluent reduced the overall risk of MACE by 15% (HR=0.85, CI: 0.78-0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, ischemic stroke, death from coronary heart disease (CHD), or unstable angina requiring hospitalization.
  • Praluent was also associated with a lower risk of death overall, known as "all-cause mortality" (HR=0.85; CI: 0.73-0.98, nominal p=0.026), and there were also numerically fewer CHD deaths (HR=0.92; CI: 0.76-1.11, p=0.38).
  • In a pre-specified analysis, the patients with baseline LDL-C levels at or above 100 mg/dL (2.6 mmol/L) experienced a more pronounced effect from Praluent, reducing their risk of MACE by 24% (HR=0.76, CI: 0.65-0.87). In a post-hoc analysis of this group, Praluent was associated with a lower risk of death from any cause by 29% (HR=0.71, CI: 0.56-0.90).
  • The analyses described above include the results from 730 patients (8%) in the Praluent group who continued to be assessed in the Praluent arm despite stopping active Praluent therapy, as specified in the protocol for patients with persistent LDL-C readings below 15 mg/dL.
  • For those in the Praluent treatment arm, approximately 75% of patient time was on the 75 mg dose.
  • There were no new safety signals in the trial, with injection site reactions experienced more commonly in the Praluent group compared to patients on maximally-tolerated statins alone (3.8% Praluent; 2.1% placebo). There was no difference in neurocognitive events (1.5% Praluent; 1.8% placebo) or new-onset diabetes (9.6% Praluent; 10.1% placebo).

    "This trial was consistent with earlier statin trials, showing the greatest benefit in patients with higher cholesterol levels at baseline," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, Regeneron. "Many patients who have survived a recent heart attack or other coronary event are unable to reach an LDL cholesterol goal of less than 100 mg/dL, and have an urgent need for new therapeutic options because of their increased risk of another event. In this trial, such patients who received Praluent on top of maximally-tolerated statins had important reductions in their risk."

    "Not all patients with heart disease are the same. Through this trial, we have been able to identify high-risk patients treated with optimal statins who still have an urgent need for additional treatment options," said Elias Zerhouni, M.D., President, Global R&D, Sanofi. "With nearly 90 percent of the patients in this trial on high-intensity statins, the data demonstrate that a precision-medicine approach in the field of cardiovascular disease may further advance how we better treat high-risk patients."

    "The results of this study, the only one specifically designed to evaluate the long-term clinical benefit of Praluent initiation with patients post acute coronary syndrome, demonstrate the value that Praluent can bring to the health of those who are unable to reach their LDL-C health goals," claimed Niven Al-Khoury, President, Sanofi Canada. "With over 60 years of experience working to understand and support the healthcare needs of patients, bringing valuable solutions is core to our purpose."

About ODYSSEY OUTCOMES
ODYSSEY OUTCOMES (n=18,924) assessed the effect of Praluent on the occurrence of MACE in patients who had experienced an ACS between 1-12 months (median 2.6 months) before enrolling in the trial, and who were already on maximally-tolerated statins. All patients were randomized to receive Praluent (n=9,462) or a placebo (n=9,462) and were treated for an average (median) of 2.8 years, with some patients being treated for up to five years. Approximately 90% of patients were on a high-intensity statin.

The trial was designed to maintain patients' LDL-C levels between 25-50 mg/dL (0.6 -1.3 mmol/L), using two different doses of Praluent (75 mg and 150 mg). Praluent-treated patients started the trial on 75 mg every 2 weeks, and switched to 150 mg every 2 weeks if their LDL-C levels remained above 50 mg/dL (1.3 mmol/L) (n=2,615). Some patients who switched to 150 mg switched back to 75 mg if their LDL-C fell below 25 mg/dL (0.6 mmol/L) (n=805), and patients who experienced two consecutive LDL-C measurements below 15 mg/dL (0.4 mmol/L) while on the 75 mg dose (n=730) stopped active Praluent therapy for the remainder of the trial.

About Praluent
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which lowers LDL-C levels in the blood. The use of Praluent to reduce the risk of MACE is investigational and has not been evaluated by any regulatory agency.

Praluent is approved in more than 60 countries worldwide, including the U.S., Japan, Canada, Switzerland, Mexico and Brazil, as well as the European Union (EU).

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

The effect of Praluent on cardiovascular morbidity and mortality has not been determined.

For the product monograph: http://products.sanofi.ca/en/praluent.pdf

About Regeneron Pharmaceuticals, Inc
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About Sanofi
Sanofi (EURONEXT: SAN) (NYSE: SNY) is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi entities in Canada employ close to 1,900 people. In 2016 we invested $130 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

Sanofi, Empowering Life

 

SOURCE SANOFI

86 Unbelievable Facts About Running (Infographic)

Each day, millions of people from all around the world go for a run. Some run marathons, some go out for a jogging session, and some venture into the mountains for an uphill sprint. However, all of these runners have one thing in common; they are all healthy.

It’s no secret that running is one of the healthiest activities that you can take on. From the numerous cardiovascular benefits to the powerful calorie-burning properties, regular running will help you keep your body healthy and in shape for many years to come. Moreover, running is an activity for people of all ages. The youngest marathon finisher was only five years old at the time of the race, and the oldest one was 101.

However, like every other dynamic activity, running requires preparation, adequate equipment, and caution. While running itself has no downsides, running-related injuries are more common than you may think. In fact, 65% of all runners suffer an injury within their first year of running.

So, as quality equipment is key, make sure you buy a pair of legitimate running shoes – Nike is an outstanding brand offering just that! Warm up properly, play some music over your headphones, and you are ready for a run. But before you do all that, make sure you read the other running facts in the infographic below; you will be motivated even more.

 

Losing weight and staying fit and healthy are consistently among the top 10 New Year’s resolutions, but 80 percent of people fail to keep their resolutions longer than six weeks.  March is about the time that most resolutions will be abandoned - mainly because they haven’t produced any immediate results.  Dianna Forsberg (http://diannaforsberg.com), international fitness model and health and wellness coach, outlines the best ways to stay on track to reach your fitness goals in the New Year.

1. Reality check.  Recognize the stressors in your life. Don’t ignore them.  When we ignore them, we continue to use those “coping mechanisms”, which is usually consuming junk food, unhealthy beverages and we hardly make time to workout because we are lacking energy.

2. Write out your desired goals. It can be as small as incorporating more fruits and vegetables. Working out 30 min a day, 3 times a week. Lose 5-10 lbs with 4-6 weeks. Whatever YOUR goal is, write it down.

3. Find a support system.  Everyone wants to feel better and do better.  The average person is happy to lose 5-10 lbs and maintain it. Talk to your close friends about your goals. Make a Facebook post and see who wants to join you. We are more likely to commit when we have an accountability partner.

4. Invest in a trainer, consultant or health and wellness coach to help you succeed. Seeking professional help from a third party usually works best. In most cases, we tend to take advice and guidance better from a professional.

5.  Meal prep once or twice a week to save time. Plan your workouts. Figure out if you will workout before or after work. Stick to the plan. Once you remove the junk from your regime, just say NO!  Reach for healthy snacks like unsalted almonds, banana, a green apple, cucumber slices, hard boiled eggs, fresh berries, etc.

6. Now that you have recognized what wasn’t working just a few short weeks ago. Now it’s time to truly commit, be consistent and get it done!

 

Image

Image

 

March 7, 2018 (Waterloo, ON) - Local not-for-profit STEM Camp looks to Dragons’ Den for help to solve Canadian Girls in STEM issue

For a full Media Kit with pictures goes to Newsroom.

 

Content:

It is well known that Canada does not come close to gender parity in STEM-related fields.1 Why is this? And, why is this an issue? According to STEM Camp CEO, Kevin Cougler, the answer to the first question is a challenge but the answer to the second question is simply that it’s a numbers game.

 

“If we look at gender parity as a purely mathematical concept, we would begin by agreeing that, if we aren’t attracting enough girls to STEM careers it is a potentially untapped market”, indicates Cougler. “Why wouldn’t we want the best and brightest minds in our STEM fields? The more girls we can inspire to consider these careers the better chance we have of finding the best people.”

 

Cougler feels the Dragons could help. “Not attracting girls to STEM careers is a generational and national challenge. The Dragons’ Den is a national program that could bring much needed attention to this issue. With the help of the Dragons we may be able to inspire parents to talk about the career opportunities available for their girls and the importance that STEM education will play in a future where 80-90% of jobs will require STEM skills” stated Cougler. “That’s what today was all about in our quest to be chosen for CBC’s Dragons’ Den.”

 

STEM Camp is a Canadian not -for-profit summer camp that was started by Cougler in 2013 with a mission to inspire and prepare today’s youth for a future of STEM careers. At the camp, youth participate in Science, Technology, Engineering and Mathematics (STEM) activities that are designed to be fun and engaging. Since 2013, STEM Camp has grown from 2 locations and 80 campers to 77 locations and an estimated 15,000 campers during the summer of 2018. Cougler was joined today by his father Ron, Executive Director, and their new friends Blaine and Rosie who participated in a contest where they had to convince their parents that they should be the first girl to go to the moon. They convinced their parents but also STEM Camp!

 

It is of interest to note that STEM Camp’s enrolments of girls has seen a steady increase each year, bringing girls one step closer to gender parity.  While Cougler still doesn’t know the answer to question one (1) above, he is encouraged by the small contribution his summer STEM Camp is making to the problem. Learn more from STEM Camp’s website2, Facebook. Instagram and Twitter.

 

Resources

1 http://www.statcan.gc.ca/pub/75-006-x/2013001/article/11874-eng.pdf

2 Website: stemcamp.ca

 

STEM Camp Contact Information

Larissa Mendonca, Marketing and Communications Coordinator

STEM Camp

t: 519-475-6600 x11

e: lmendonca@stemcamp.ca